An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer
NCT ID: NCT02750514
Last Updated: 2021-03-22
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
295 participants
INTERVENTIONAL
2016-05-09
2020-01-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC
NCT03425331
Nivolumab in Treating Patients With Advanced Metastatic Non-small Cell Lung Cancer
NCT03121417
An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers
NCT02869789
Ipilimumab and Nivolumab in Patients With Anti-PD-1-axis Therapy-resistant Advanced Non-small Cell Lung Cancer.
NCT03262779
Phase I Multicenter Trial Combining Nivolumab, Ipilimumab and Hypo-fractionated Radiotherapy for Pretreated Advanced Stage Non-small Cell Lung Cancer Patients
NCT03509584
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Nivolumab
Nivolumab Monotherapy - Arm associated with this intervention is closed. Nivolumab is no longer given as an active comparator
Nivolumab
Arm associated with this intervention is closed. Nivolumab is no longer given as an active comparator.
Nivolumab & Dasatinib
Nivolumab in combination with Dasatinib
Nivolumab
Arm associated with this intervention is closed. Nivolumab is no longer given as an active comparator.
Dasatinib
Nivolumab & Relatlimab
Nivolumab in combination with Relatlimab
Nivolumab
Arm associated with this intervention is closed. Nivolumab is no longer given as an active comparator.
Relatlimab
Nivolumab & Ipilimumab
Nivolumab in combination with Ipilimumab
Nivolumab
Arm associated with this intervention is closed. Nivolumab is no longer given as an active comparator.
Ipilimumab
Nivolumab & BMS-986205
Nivolumab in combination with BMS- 986205
Nivolumab
Arm associated with this intervention is closed. Nivolumab is no longer given as an active comparator.
BMS-986205
Specified dose on specified days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Nivolumab
Arm associated with this intervention is closed. Nivolumab is no longer given as an active comparator.
Dasatinib
Relatlimab
Ipilimumab
BMS-986205
Specified dose on specified days
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Eastern Cooperative Oncology Group (ECOG) Performance status of ≤ 1
* Life expectancy of at least 3 months from most recent chemotherapy or immunotherapy treatment
* Must have at least 1 lesion with measurable disease
Exclusion Criteria
* Subjects who need daily oxygen therapy
* People with autoimmune disease
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bristol-Myers Squibb
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Bristol-Myers Squibb
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
City of Hope National Medical Center
Duarte, California, United States
University of Southern California (USC)
Los Angeles, California, United States
Cedars-Sinai Medical Center
Los Angeles, California, United States
University of Californa, Los Angeles (UCLA)
Los Angeles, California, United States
Hoag Memorial Hospital Presbyterian
Newport Beach, California, United States
University of California San Diego
San Diego, California, United States
University of Colorado Denver
Aurora, Colorado, United States
Yale Cancer Center
New Haven, Connecticut, United States
University of Kansas Cancer Center
Westwood, Kansas, United States
University of Maryland - Marlene and Stewart Greenebaum Cancer Center
Baltimore, Maryland, United States
Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
Dana Farber/Harvard Cancer Center
Boston, Massachusetts, United States
University of Michigan Health System (UMHS) - University Hospital (University of Michigan Medical Ce
Ann Arbor, Michigan, United States
Karmanos Cancer Institute
Detroit, Michigan, United States
Washington University, The Center for Advanced Medicine
St Louis, Missouri, United States
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, United States
Roswell Park Cancer Institute
Buffalo, New York, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Univ of NC Shool of Medicine
Chapel Hill, North Carolina, United States
The Ohio State University
Columbus, Ohio, United States
Northwest Cancer Specialists
Portland, Oregon, United States
Thomas Jefferson University
Philadelphia, Pennsylvania, United States
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States
The West Clinic, P.C. d/b/a West Cancer Center
Germantown, Tennessee, United States
Sarah Cannon Cancer Center
Nashville, Tennessee, United States
Sammons Cancer Center (Uso)
Dallas, Texas, United States
Texas Oncology, P.A.
Fort Worth, Texas, United States
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Us Oncology
Tyler, Texas, United States
Huntsman Cancer Institute
Salt Lake City, Utah, United States
Virginia Cancer Specialists, PC
Fairfax, Virginia, United States
University of Washington-Seattle Cancer Care Alliance
Seattle, Washington, United States
Local Institution
Clayton, Victoria, Australia
Local Institution
Salzburg, , Austria
Juravinski Cancer Centre, Hamilton Health Sciences-Mcmaster Univeristy's Faculty Of Health Sciences
Hamilton, Ontario, Canada
University Of Ottawa - The Ottawa Hospital Cancer centre
Ottawa, Ontario, Canada
Local Institution
Edmonton, , Canada
Local Institution
Paris, , France
Local Institution
Toulouse, , France
Local Institution
Villejuif, , France
Local Institution
Milan, , Italy
Local Institution
Milan, , Italy
Local Institution
Rozzano, , Italy
Local Institution
Madrid, , Spain
Local Institution
Madrid, , Spain
Local Institution
Pamplona, , Spain
Local Institution
Lausanne, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Statistical Analysis Plan
Document Type: Study Protocol
Related Links
Access external resources that provide additional context or updates about the study.
BMS Clinical Trial Information
BMS Clinical Trial Patient Recruiting
Investigator Inquiry Form
FDA Safety Alerts and Recalls
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CA018-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.